Delayed Settlement Resolved

Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”). The Placing was approved at a shareholder meeting on 26 August 2026, and the Placing Shares were admitted to trading on AIM on 27 August 2026.

On 1 October 2026 the Company further announced that the proceeds of the Placing were received by the Company at the time of Admission in accordance with the terms of the Placing Agreement, save for £250,000 in respect of 250,000,000 Placing Shares that had still to be received from Vulpes Investment Management (“Vulpes”) and that the Company, Singer Capital Markets and Merlin Partners LLP, who are parties to the Placing Agreement, had agreed to extend the time period under the Placing Agreement for payment to 30 October 2026.

The Company announces the 250,000,000 Placing Shares have now been placed at £0.001 per share with three separate investors, each of whom is an existing shareholder, with Vulpes’ consent. Accordingly, the Placing has now completed and the Company will receive the gross proceeds of £9.15m from the Placing in full.

Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.